Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL

Clinical trial NCT04705129 · UNKNOWN

Trial details

NCT number: NCT04705129
Sponsor: Ruijin Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Mediastinal Large B Cell Lymphoma EBV-Positive DLBCL, Nos

Start date: 2021-01-01
Primary completion: 2023-01-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.